$ICPT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in INTERCEPT PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in INTERCEPT PHARMACEUTICALS, INC.. Get notifications about new insider transactions in INTERCEPT PHARMACEUTICALS, INC. for free.
Page: < prev 1 ... 8 9 10 11 12 13 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 13 2013 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Option Exercise | M | 10.11 | 3,461 | 34,995 | 0 | |
| Aug 13 2013 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Option Exercise | M | 0.00 | 325 | 0 | 1,298 | |
| Aug 13 2013 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Sell | S | 46.18 | 3,959 | 182,843 | 1,330 | 5.3 K to 1.3 K (-74.85 %) |
| Aug 13 2013 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Sell | S | 45.89 | 800 | 36,709 | 5,289 | 6.1 K to 5.3 K (-13.14 %) |
| Aug 13 2013 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Buy | M | 10.11 | 3,461 | 34,995 | 6,089 | 2.6 K to 6.1 K (+131.70 %) |
| Aug 13 2013 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Buy | M | 0.00 | 325 | 0 | 2,628 | 2.3 K to 2.6 K (+14.11 %) |
| Aug 13 2013 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | M | 0.00 | 368 | 0 | 1,471 | |
| Aug 13 2013 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Buy | M | 0.00 | 368 | 0 | 2,801 | 2.4 K to 2.8 K (+15.13 %) |
| Aug 13 2013 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Option Exercise | M | 0.00 | 325 | 0 | 1,298 | |
| Aug 13 2013 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Buy | M | 0.00 | 325 | 0 | 2,151,932 | 2.2 M to 2.2 M (+0.02 %) |
| Jul 24 2013 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 10.40 | 2,000 | 20,800 | 17,634 | |
| Jul 24 2013 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 50.34 | 1,000 | 50,342 | 5,094 | 6.1 K to 5.1 K (-16.41 %) |
| Jul 24 2013 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 48.54 | 1,000 | 48,542 | 6,094 | 7.1 K to 6.1 K (-14.10 %) |
| Jul 24 2013 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 10.40 | 2,000 | 20,800 | 7,094 | 5.1 K to 7.1 K (+39.26 %) |
| Jul 16 2013 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Option Exercise | M | 0.00 | 325 | 0 | 1,622 | |
| Jul 16 2013 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Buy | M | 0.00 | 325 | 0 | 2,304 | 2 K to 2.3 K (+16.42 %) |
| Jul 16 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Option Exercise | M | 9.82 | 21,700 | 213,144 | 29,806 | |
| Jul 16 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Option Exercise | M | 9.82 | 3,300 | 32,414 | 51,506 | |
| Jul 16 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Sell | S | 50.64 | 1,659 | 84,008 | 402,032 | 403.7 K to 402 K (-0.41 %) |
| Jul 16 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Sell | S | 49.78 | 20,041 | 997,675 | 403,691 | 423.7 K to 403.7 K (-4.73 %) |
| Jul 16 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Buy | M | 9.82 | 21,700 | 213,144 | 423,732 | 402 K to 423.7 K (+5.40 %) |
| Jul 16 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Sell | S | 51.83 | 1,300 | 67,374 | 402,032 | 403.3 K to 402 K (-0.32 %) |
| Jul 16 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Sell | S | 51.04 | 2,000 | 102,072 | 403,332 | 405.3 K to 403.3 K (-0.49 %) |
| Jul 16 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Buy | M | 9.82 | 3,300 | 32,414 | 405,332 | 402 K to 405.3 K (+0.82 %) |
| Jul 10 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 9.82 | 25,000 | 245,558 | 19,520 | |
| Jul 10 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 45.39 | 25,000 | 1,134,840 | 8,112 | 33.1 K to 8.1 K (-75.50 %) |
| Jul 10 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 9.82 | 25,000 | 245,558 | 33,112 | 8.1 K to 33.1 K (+308.19 %) |
| Jul 10 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Option Exercise | M | 9.82 | 10,097 | 99,176 | 54,806 | |
| Jul 10 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Option Exercise | M | 9.82 | 2,403 | 23,603 | 0 | |
| Jul 10 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Option Exercise | M | 9.82 | 25,000 | 245,558 | 2,403 | |
| Jul 10 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Sell | S | 48.26 | 12,500 | 603,259 | 402,032 | 414.5 K to 402 K (-3.02 %) |
| Jul 10 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Buy | M | 9.82 | 10,097 | 99,176 | 414,532 | 404.4 K to 414.5 K (+2.50 %) |
| Jul 10 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Buy | M | 9.82 | 2,403 | 23,603 | 404,435 | 402 K to 404.4 K (+0.60 %) |
| Jul 10 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Sell | S | 45.41 | 25,000 | 1,135,200 | 402,032 | 427 K to 402 K (-5.85 %) |
| Jul 10 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Buy | M | 9.82 | 25,000 | 245,558 | 427,032 | 402 K to 427 K (+6.22 %) |
| Jul 03 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 0.00 | 1,298 | 0 | 12,981 | |
| Jul 03 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 0.00 | 1,298 | 0 | 8,112 | 6.8 K to 8.1 K (+19.05 %) |
| Jul 03 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO & EVP - Develop ... | Option Exercise | M | 10.40 | 3,750 | 39,000 | 71,538 | |
| Jul 03 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO & EVP - Develop ... | Option Exercise | M | 0.00 | 1,623 | 0 | 16,225 | |
| Jul 03 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO & EVP - Develop ... | Sell | S | 43.63 | 4,369 | 190,623 | 3,536 | 7.9 K to 3.5 K (-55.27 %) |
| Jul 03 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO & EVP - Develop ... | Buy | M | 10.40 | 3,750 | 39,000 | 7,905 | 4.2 K to 7.9 K (+90.25 %) |
| Jul 03 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO & EVP - Develop ... | Buy | M | 0.00 | 1,623 | 0 | 4,155 | 2.5 K to 4.2 K (+64.10 %) |
| Jul 03 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Option Exercise | M | 0.00 | 4,868 | 0 | 48,677 | |
| Jul 03 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Buy | M | 0.00 | 4,868 | 0 | 406,900 | 402 K to 406.9 K (+1.21 %) |
| Jul 03 2013 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 0.00 | 649 | 0 | 6,490 | |
| Jul 03 2013 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 0.00 | 649 | 0 | 5,094 | 4.4 K to 5.1 K (+14.60 %) |
| Jun 27 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Option Exercise | M | 9.82 | 12,300 | 120,814 | 27,403 | |
| Jun 27 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Option Exercise | M | 9.82 | 200 | 1,964 | 39,703 | |
| Jun 27 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Sell | S | 40.06 | 12,300 | 492,745 | 402,032 | 414.3 K to 402 K (-2.97 %) |
| Jun 27 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Buy | M | 9.82 | 12,300 | 120,814 | 414,332 | 402 K to 414.3 K (+3.06 %) |
| Jun 27 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Sell | S | 40.00 | 200 | 8,000 | 402,032 | 402.2 K to 402 K (-0.05 %) |
| Jun 27 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Buy | M | 9.82 | 200 | 1,964 | 402,232 | 402 K to 402.2 K (+0.05 %) |
| Jun 24 2013 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 10.40 | 2,000 | 20,800 | 19,634 | |
| Jun 24 2013 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 37.11 | 900 | 33,399 | 4,445 | 5.3 K to 4.4 K (-16.84 %) |
| Jun 24 2013 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 37.10 | 200 | 7,420 | 5,345 | 5.5 K to 5.3 K (-3.61 %) |
| Jun 24 2013 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 37.04 | 400 | 14,816 | 5,545 | 5.9 K to 5.5 K (-6.73 %) |
| Jun 24 2013 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 37.01 | 100 | 3,701 | 5,945 | 6 K to 5.9 K (-1.65 %) |
| Jun 24 2013 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 37.00 | 400 | 14,800 | 6,045 | 6.4 K to 6 K (-6.21 %) |
| Jun 24 2013 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 10.40 | 2,000 | 20,800 | 6,445 | 4.4 K to 6.4 K (+44.99 %) |
| Jun 21 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 9.82 | 42,018 | 412,713 | 44,520 | |
| Jun 21 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 8.67 | 8,557 | 74,161 | 8,940 | |
| Jun 21 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 34.50 | 50,575 | 1,744,838 | 6,814 | 57.4 K to 6.8 K (-88.13 %) |
| Jun 21 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 9.82 | 42,018 | 412,713 | 56,759 | 14.7 K to 56.8 K (+285.04 %) |
| Jun 21 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 8.67 | 8,557 | 74,161 | 14,741 | 6.2 K to 14.7 K (+138.37 %) |
| Jun 21 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Option Exercise | M | 9.82 | 16,000 | 157,157 | 39,903 | |
| Jun 21 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Option Exercise | M | 9.82 | 9,000 | 88,401 | 55,903 | |
| Jun 21 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Sell | S | 38.35 | 16,000 | 613,597 | 402,032 | 418 K to 402 K (-3.83 %) |
| Jun 21 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Buy | M | 9.82 | 16,000 | 157,157 | 418,032 | 402 K to 418 K (+3.98 %) |
| Jun 21 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Sell | S | 38.08 | 9,000 | 342,751 | 402,032 | 411 K to 402 K (-2.19 %) |
| Jun 21 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Buy | M | 9.82 | 9,000 | 88,401 | 411,032 | 402 K to 411 K (+2.24 %) |
| Jun 19 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO & EVP - Develop ... | Option Exercise | M | 10.40 | 3,750 | 39,000 | 75,288 | |
| Jun 19 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO & EVP - Develop ... | Sell | S | 32.75 | 700 | 22,925 | 2,532 | 3.2 K to 2.5 K (-21.66 %) |
| Jun 19 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO & EVP - Develop ... | Sell | S | 32.75 | 3,316 | 108,599 | 3,232 | 6.5 K to 3.2 K (-50.64 %) |
| Jun 19 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO & EVP - Develop ... | Sell | S | 32.60 | 1,000 | 32,600 | 6,548 | 7.5 K to 6.5 K (-13.25 %) |
| Jun 19 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO & EVP - Develop ... | Buy | M | 10.40 | 3,750 | 39,000 | 7,548 | 3.8 K to 7.5 K (+98.74 %) |
| May 28 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 8.67 | 4,915 | 42,597 | 17,497 | |
| May 28 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 8.67 | 1,200 | 10,400 | 22,412 | |
| May 28 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 8.67 | 110 | 953 | 23,612 | |
| May 28 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 34.50 | 4,915 | 169,568 | 6,814 | 11.7 K to 6.8 K (-41.90 %) |
| May 28 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 8.67 | 4,915 | 42,597 | 11,729 | 6.8 K to 11.7 K (+72.13 %) |
| May 28 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 34.50 | 1,200 | 41,400 | 6,814 | 8 K to 6.8 K (-14.97 %) |
| May 28 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 8.67 | 1,200 | 10,400 | 8,014 | 6.8 K to 8 K (+17.61 %) |
| May 28 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 34.54 | 110 | 3,799 | 6,814 | 6.9 K to 6.8 K (-1.59 %) |
| May 28 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 8.67 | 110 | 953 | 6,924 | 6.8 K to 6.9 K (+1.61 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 496 | 5,158 | 79,038 | |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 3,254 | 33,842 | 79,534 | |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.30 | 100 | 3,130 | 3,798 | 3.9 K to 3.8 K (-2.57 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.26 | 100 | 3,126 | 3,898 | 4 K to 3.9 K (-2.50 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.22 | 662 | 20,668 | 3,998 | 4.7 K to 4 K (-14.21 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.22 | 435 | 13,581 | 4,660 | 5.1 K to 4.7 K (-8.54 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.20 | 465 | 14,508 | 5,095 | 5.6 K to 5.1 K (-8.36 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 496 | 5,158 | 5,560 | 5.1 K to 5.6 K (+9.79 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.74 | 100 | 3,174 | 5,064 | 5.2 K to 5.1 K (-1.94 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.70 | 300 | 9,509 | 5,164 | 5.5 K to 5.2 K (-5.49 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.58 | 100 | 3,158 | 5,464 | 5.6 K to 5.5 K (-1.80 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.56 | 100 | 3,156 | 5,564 | 5.7 K to 5.6 K (-1.77 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.54 | 200 | 6,308 | 5,664 | 5.9 K to 5.7 K (-3.41 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.50 | 80 | 2,520 | 5,864 | 5.9 K to 5.9 K (-1.35 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.46 | 10 | 315 | 5,944 | 6 K to 5.9 K (-0.17 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.40 | 100 | 3,140 | 5,954 | 6.1 K to 6 K (-1.65 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.39 | 100 | 3,139 | 6,054 | 6.2 K to 6.1 K (-1.62 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.37 | 100 | 3,137 | 6,154 | 6.3 K to 6.2 K (-1.60 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.35 | 838 | 26,271 | 6,254 | 7.1 K to 6.3 K (-11.82 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.29 | 120 | 3,754 | 7,092 | 7.2 K to 7.1 K (-1.66 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.27 | 10 | 313 | 7,212 | 7.2 K to 7.2 K (-0.14 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.23 | 90 | 2,811 | 7,222 | 7.3 K to 7.2 K (-1.23 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.19 | 200 | 6,238 | 7,312 | 7.5 K to 7.3 K (-2.66 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.14 | 100 | 3,114 | 7,512 | 7.6 K to 7.5 K (-1.31 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.13 | 500 | 15,565 | 7,612 | 8.1 K to 7.6 K (-6.16 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.12 | 90 | 2,801 | 8,112 | 8.2 K to 8.1 K (-1.10 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 31.11 | 20 | 622 | 8,202 | 8.2 K to 8.2 K (-0.24 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 30.99 | 30 | 930 | 8,222 | 8.3 K to 8.2 K (-0.36 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 30.98 | 50 | 1,549 | 8,252 | 8.3 K to 8.3 K (-0.60 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 30.70 | 16 | 491 | 8,302 | 8.3 K to 8.3 K (-0.19 %) |
| May 20 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 3,254 | 33,842 | 8,318 | 5.1 K to 8.3 K (+64.26 %) |
| May 22 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 8.67 | 23,873 | 206,900 | 23,722 | |
| May 22 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 21.50 | 4,327 | 93,031 | 9,519 | |
| May 22 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 34.50 | 100 | 3,450 | 6,814 | 6.9 K to 6.8 K (-1.45 %) |
| May 22 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 34.50 | 100 | 3,450 | 6,914 | 7 K to 6.9 K (-1.43 %) |
| May 22 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 34.50 | 28,000 | 966,000 | 7,014 | 35 K to 7 K (-79.97 %) |
| May 22 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 8.67 | 23,873 | 206,900 | 35,014 | 11.1 K to 35 K (+214.28 %) |
| May 22 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 21.50 | 4,327 | 93,031 | 11,141 | 6.8 K to 11.1 K (+63.50 %) |
| May 13 2013 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Option Exercise | M | 0.00 | 324 | 0 | 1,623 | |
| May 13 2013 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Buy | M | 0.00 | 324 | 0 | 2,151,607 | 2.2 M to 2.2 M (+0.02 %) |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Option Exercise | A | 31.90 | 2,450 | 78,155 | 2,450 | |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Grant | A | 0.00 | 1,640 | 0 | 1,640 | 0 to 1.6 K |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | A | 31.90 | 1,980 | 63,162 | 1,980 | |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 0.00 | 324 | 0 | 1,623 | |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Grant | A | 0.00 | 1,330 | 0 | 2,303 | 973 to 2.3 K (+136.69 %) |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 0.00 | 324 | 0 | 973 | 649 to 973 (+49.92 %) |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Option Exercise | A | 31.90 | 65,000 | 2,073,500 | 65,000 | |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Grant | A | 0.00 | 7,700 | 0 | 402,032 | 394.3 K to 402 K (+1.95 %) |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Option Exercise | A | 31.90 | 1,980 | 63,162 | 1,980 | |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Option Exercise | M | 0.00 | 324 | 0 | 1,623 | |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Grant | A | 0.00 | 1,330 | 0 | 2,303 | 973 to 2.3 K (+136.69 %) |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Buy | M | 0.00 | 324 | 0 | 973 | 649 to 973 (+49.92 %) |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | SEE REMARKS | Option Exercise | A | 31.90 | 22,500 | 717,750 | 22,500 | |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | SEE REMARKS | Grant | A | 0.00 | 3,000 | 0 | 8,064 | 5.1 K to 8.1 K (+59.24 %) |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Option Exercise | A | 31.90 | 1,980 | 63,162 | 1,980 | |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Option Exercise | M | 0.00 | 324 | 0 | 1,623 | |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Grant | A | 0.00 | 1,330 | 0 | 2,303 | 973 to 2.3 K (+136.69 %) |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Buy | M | 0.00 | 324 | 0 | 973 | 649 to 973 (+49.92 %) |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | A | 31.90 | 22,500 | 717,750 | 22,500 | |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Grant | A | 0.00 | 3,000 | 0 | 6,814 | 3.8 K to 6.8 K (+78.66 %) |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Option Exercise | A | 31.90 | 1,980 | 63,162 | 1,980 | |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Grant | A | 0.00 | 1,330 | 0 | 1,979 | 649 to 2 K (+204.93 %) |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | A | 31.90 | 4,900 | 156,310 | 4,900 | |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Grant | A | 0.00 | 1,200 | 0 | 4,445 | 3.2 K to 4.4 K (+36.98 %) |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | A | 31.90 | 1,980 | 63,162 | 1,980 | |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | M | 0.00 | 368 | 0 | 1,839 |